Association Between Peptide Antigen-Related Antibody Levels and the Short- and Long-Term Efficacy of Antipsychotic Treatment in Drug-Naïve First-Episode Schizophrenia Patients DOI
Yue Zheng, Jian Du, Mingqia Wang

et al.

Schizophrenia Bulletin, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 22, 2024

Abstract Objective This study investigated the relationships between baseline peptide antigen-related IgG levels and 8-week antipsychotic drug (APD) treatment response rates one-year outcomes, as well changes in first-episode schizophrenia (FES) patients. Methods Sixteen IgGs from proteins encoded by schizophrenia-related genes were selected on basis of several selection criteria a 2022 genome-wide association study. Novel measured drug-naïve FES patients at (n = 155) plasma samples 60 healthy controls (HCs). At follow-up, 57 completed both symptom autoantibody assessments. Statistical analyses included t tests, Pearson correlation analysis, linear regression mixed-effects models, simple slope analysis. Results Anti-MOB4 anti-PDIA3 significantly lower compared to HCs showed negative with excitement factor scores. Baseline anti-EMB associated response, whereas anti-MAD1L1 correlated outcomes The trajectory anti-FURIN IgG, anti-MAPK3 anti-ACTR1B was related remission. Conclusion revealed that had autoimmune abnormalities, different being short-term or long-term efficacy, these antibody regulated APDs.

Language: Английский

Association Between Peptide Antigen-Related Antibody Levels and the Short- and Long-Term Efficacy of Antipsychotic Treatment in Drug-Naïve First-Episode Schizophrenia Patients DOI
Yue Zheng, Jian Du, Mingqia Wang

et al.

Schizophrenia Bulletin, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 22, 2024

Abstract Objective This study investigated the relationships between baseline peptide antigen-related IgG levels and 8-week antipsychotic drug (APD) treatment response rates one-year outcomes, as well changes in first-episode schizophrenia (FES) patients. Methods Sixteen IgGs from proteins encoded by schizophrenia-related genes were selected on basis of several selection criteria a 2022 genome-wide association study. Novel measured drug-naïve FES patients at (n = 155) plasma samples 60 healthy controls (HCs). At follow-up, 57 completed both symptom autoantibody assessments. Statistical analyses included t tests, Pearson correlation analysis, linear regression mixed-effects models, simple slope analysis. Results Anti-MOB4 anti-PDIA3 significantly lower compared to HCs showed negative with excitement factor scores. Baseline anti-EMB associated response, whereas anti-MAD1L1 correlated outcomes The trajectory anti-FURIN IgG, anti-MAPK3 anti-ACTR1B was related remission. Conclusion revealed that had autoimmune abnormalities, different being short-term or long-term efficacy, these antibody regulated APDs.

Language: Английский

Citations

0